A company official has testified to a jury that a prototype of Johnson & Johnson’s (J&J) transvaginal mesh failed in 20% of women in the first six months before they began selling it. According to project leader Scott Ciarrocca, 27% of the mesh devices failed within a year when J&J began selling them in 2005.
Ciarrocca was a project leader in developing Johnson & Johnson’s Gynecare Prolift transvaginal mesh implant. The Gynecare Prolift is the subject of the first transvaginal mesh lawsuit to go to trial in New Jersey, where Linda Gross alleges the device failed and required 18 revision surgeries.
Lawyers involved in transvaginal mesh patch lawsuits predict manufacturers such as Johnson & Johnson and C. R. Bard could face thousands of lawsuits from patients who were injured by the faulty devices. Many doctors have stopped using the devices as companies halt sales amid allegations of mesh side effects, including severe pain, limited mobility and revision surgery.